In addition, we show evidence that the ErbB/PI3K/Akt/ NF-κB signalling pathway is involved in prostate cancer progression and that a multiple marker approach identifying active signalling pathways may be prognostically more relevant than single markers. This evidence concerns the gene NFKB1 and prostate cancer.